Evidence map›Paper›PMID 40956473›Full record

ArticleEndocrine2025

Detection of copy number variations by chromosomal microarray analysis in disorders of sex development of unexplained molecular etiology and association with clinical findings.

Murat Çağlar Karataş, Ferda Evin, Tahir Atik, Aysun Ata, Eren Er, Erhan Parıltay, Aslı Ece Solmaz, Damla Gökşen, Şükran Darcan, Samim Özen

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Murat Çağlar KarataşClinic of Pediatric Endocrinology, University of Health Sciences, Behçet Uz Child Disease and Pediatric Surgery Training and Research Hospital, Dr. Behçet, Izmir, Türkiye.
Ferda EvinDepartment of Pediatric Endocrinology and Diabetes, Faculty of Medicine, Ege University, Izmir, Türkiye.
Tahir AtikDepartment of Pediatric Genetics, Faculty of Medicine, Ege University, Izmir, Türkiye.
Aysun AtaDepartment of Pediatric Endocrinology and Diabetes, Faculty of Medicine, Ege University, Izmir, Türkiye.
Eren ErDepartment of Pediatric Endocrinology and Diabetes, Faculty of Medicine, Ege University, Izmir, Türkiye.
Erhan ParıltayDepartment of Medical Genetics, Faculty of Medicine, Ege University, Izmir, Türkiye.
Aslı Ece SolmazDepartment of Medical Genetics, Faculty of Medicine, Ege University, Izmir, Türkiye.
Damla GökşenDepartment of Pediatric Endocrinology and Diabetes, Faculty of Medicine, Ege University, Izmir, Türkiye.
Şükran DarcanDepartment of Pediatric Endocrinology and Diabetes, Faculty of Medicine, Ege University, Izmir, Türkiye.
Samim ÖzenDepartment of Pediatric Endocrinology and Diabetes, Faculty of Medicine, Ege University, Izmir, Türkiye. samim.ozen@ege.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDespite advances in genetic diagnostics, the molecular cause of a significant proportion of DSDs remains unknown. The aim of this study was to identify copy number variations (CNVs) using chromosomal microarray analysis (CMA) technology in DSD patients with previously undetected molecular genetic etiology and to investigate their phenotypic associations with these variations.

methodsThis study included DSD cases without chromosomal abnormalities and without any variants detected by sequence analysis methods, including whole-exome sequencing analysis. We evaluated variant pathogenicity according to the American College of Medical Genetics and Genomics guidelines and recorded the phenotypic findings of the cases. All pathogenic variants were subjected to segregation analysis.

resultsOf the 20 patients included in the study, 16 (80%) were classified as 46,XY DSD and 4 (20%) as 46,XX DSD. Initial clinical diagnoses in this 46,XX DSD group included gonadal dysgenesis in two patients (50%) and androgen excess in the remaining two (50%). Among the 46,XY DSD patients, five patients (31.25%) were presumed to be androgen insensitive, nine (56.25%) were diagnosed with defects in androgen biosynthesis, and two (12.5%) had gonadal dysgenesis. CMA detected 38 CNVs in 16 patients (80%), comprising 12 deletions (31.6%) and 26 duplications (68.4%). Three pathogenic CNVs were detected in 3 patients (15%), whereas 27 variants of uncertain significance were identified in 13 patients (65%).

conclusionIn selected cases, the diagnostic approach should incorporate CMA to elucidate the molecular etiology of DSD. Furthermore, CMA may prove to be an invaluable tool in the search for new genes responsible for DSD.

Indexed as

Disorders of Sex DevelopmentDNA Copy Number VariationsAdolescentChildChild, PreschoolFemaleGonadal Dysgenesis, 46,XYHumansInfantMaleMicroarray AnalysisOligonucleotide Array Sequence AnalysisChromosomal microarray analysisCopy number variationDisorders of sex development

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.